Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia

Haematologica. 2019 Aug;104(8):e376-e379. doi: 10.3324/haematol.2019.217141. Epub 2019 Apr 11.

Affiliations

¹ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto.
² Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
³ Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto [email protected].

No abstract available

Publication types

Letter

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / adverse effects
Cyclophosphamide / therapeutic use
Doxorubicin / adverse effects
Doxorubicin / therapeutic use
Epstein-Barr Virus Infections / complications*
Epstein-Barr Virus Infections / virology
Herpesvirus 4, Human / physiology*
Humans
Imatinib Mesylate / adverse effects*
Imatinib Mesylate / therapeutic use
Immunohistochemistry
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Lymph Nodes / pathology
Lymphoproliferative Disorders / diagnosis*
Lymphoproliferative Disorders / etiology*
Male
Prednisone / adverse effects
Prednisone / therapeutic use
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / therapeutic use
Splenomegaly
Tomography, X-Ray Computed
Vincristine / adverse effects
Vincristine / therapeutic use

Substances

Protein Kinase Inhibitors
Vincristine
Doxorubicin
Imatinib Mesylate
Cyclophosphamide
Prednisone

Supplementary concepts

CHOP protocol